Literature DB >> 3084085

Effect of chemotherapy on NK function in the peripheral blood of cancer patients.

D P Braun, J E Harris.   

Abstract

The effects of cytotoxic chemotherapy on NK cell function and on glass adherent cell regulation of NK cell function was evaluated in the peripheral blood mononuclear cells of 20 previously untreated solid tumor patients. Most of the patients studied had lung cancer and received one of four combination chemotherapy treatment regimens. In addition, one patient with colon carcinoma and one patient with melanoma were studied, each of whom received treatment with a single agent. The results demonstrated that chemotherapy exerted a differential influence on NK activity which correlated with the pretreatment NK level of function in the individual patient. In patients with depressed NK levels prior to treatment, chemotherapy augmented NK function; in patients with normal levels prior to treatment, chemotherapy depressed NK function. The effects observed appeared to be associated with the capacity of chemotherapy to influence glass adherent cell regulation of NK activity. There was no apparent correlation between the effects of chemotherapy on numbers of NK effector cells, Leu11+ cells, or latex-ingesting cells. Also, there was no correlation between the effects seen and the type of drug treatment that was administered; rather, this was dependent on the pretreatment NK level of function which in turn was associated with glass adherent cell regulation of NK function.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3084085     DOI: 10.1007/bf00199368

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  15 in total

1.  Chemotherapy, immunocompetence, immunosuppression and prognosis in acute leukemia.

Authors:  E M Hersh; J P Whitecar; K B McCredie; G P Bodey; E J Freireich
Journal:  N Engl J Med       Date:  1971-11       Impact factor: 91.245

Review 2.  Natural killer cells and interferon.

Authors:  R M Welsh
Journal:  Crit Rev Immunol       Date:  1984       Impact factor: 2.214

3.  Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice.

Authors:  J C Hengst; M B Mokyr; S Dray
Journal:  Cancer Res       Date:  1980-07       Impact factor: 12.701

4.  Effects of combination chemotherapy on immunoregulatory cells in peripheral blood of solid tumor cancer patients: correlation with rebound overshoot immune function recovery.

Authors:  D P Braun; J E Harris
Journal:  Clin Immunol Immunopathol       Date:  1981-08

5.  Relationship of arachidonic acid metabolism to indomethacin-sensitive immunoregulatory function and lymphocyte PGE sensitivity in peripheral blood mononuclear cells of disseminated solid tumor cancer patients.

Authors:  D P Braum; J E Harris; M Rubenstein
Journal:  J Immunopharmacol       Date:  1984

6.  Indomethacin enhancement of immunocompetence in melanoma patients.

Authors:  A B Tilden; C M Balch
Journal:  Surgery       Date:  1981-07       Impact factor: 3.982

7.  Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide.

Authors:  M B Mokyr; S Dray
Journal:  Cancer Res       Date:  1983-07       Impact factor: 12.701

8.  The dual interaction of prostaglandin E2 (PGE2) and interferon (IFN) on NK lytic activation: enhanced capacity of effector-target lytic interactions (recycling) and blockage of pre-NK cell recruitment.

Authors:  S R Targan
Journal:  J Immunol       Date:  1981-10       Impact factor: 5.422

9.  Decline of natural nonselective cell-mediated cytotoxicity in patients with tumor progression.

Authors:  M Takasugi; A Ramseyer; J Takasugi
Journal:  Cancer Res       Date:  1977-02       Impact factor: 12.701

Review 10.  The effect of immunosuppressive chemotherapy on immune function in patients with malignant disease.

Authors:  J Harris; D Sengar; T Stewart; D Hyslop
Journal:  Cancer       Date:  1976-02       Impact factor: 6.860

View more
  2 in total

1.  Paradoxical enhancement of interleukin-2-mediated cytotoxicity against K562 cells by addition of a low dose of methotrexate.

Authors:  T Nakarai; Y Ueno; Y Ueno; S Koizumi
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 2.  Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.

Authors:  L Bracci; G Schiavoni; A Sistigu; F Belardelli
Journal:  Cell Death Differ       Date:  2013-06-21       Impact factor: 15.828

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.